Candel Therapeutics, Inc. (CADL) Phase 3 Subgroup Shows 41% Lower Risk of Recurrence/Death

Candel Therapeutics reported Phase 3 subgroup results showing HR 0.59 (p=0.0034) for recurrence or prostate cancer-specific death with aglatimagene plus EBRT vs placebo, and Phase 2 biomarker data indicating systemic immune activation. A BLA submission is planned for Q4 2026.Material DetailsContext…